Rapt Therapeutics (RAPT) Competitors $8.01 +0.68 (+9.28%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$7.84 -0.17 (-2.06%) As of 07/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. VALN, MAZE, SEPN, AMLX, CGEM, ATYR, SIGA, TRML, PGEN, and MREOShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Valneva (VALN), Maze Therapeutics (MAZE), Septerna (SEPN), Amylyx Pharmaceuticals (AMLX), Cullinan Therapeutics (CGEM), aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Precigen (PGEN), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Valneva Maze Therapeutics Septerna Amylyx Pharmaceuticals Cullinan Therapeutics aTyr Pharma Siga Technologies Tourmaline Bio Precigen Mereo BioPharma Group Valneva (NASDAQ:VALN) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Which has preferable valuation & earnings, VALN or RAPT? Valneva has higher revenue and earnings than Rapt Therapeutics. Valneva is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$183.52M2.68-$13.25M-$1.19-4.86Rapt Therapeutics$1.53M86.59-$129.87M-$19.20-0.42 Do institutionals and insiders hold more shares of VALN or RAPT? 11.4% of Valneva shares are owned by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 2.4% of Rapt Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer VALN or RAPT? Valneva currently has a consensus target price of $15.50, suggesting a potential upside of 168.17%. Rapt Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 199.63%. Given Rapt Therapeutics' higher possible upside, analysts plainly believe Rapt Therapeutics is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Rapt Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33 Which has more risk & volatility, VALN or RAPT? Valneva has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Does the media refer more to VALN or RAPT? In the previous week, Rapt Therapeutics had 2 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Rapt Therapeutics and 0 mentions for Valneva. Rapt Therapeutics' average media sentiment score of 0.69 beat Valneva's score of 0.62 indicating that Rapt Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Valneva Positive Rapt Therapeutics Positive Is VALN or RAPT more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -43.08%. Valneva's return on equity of -43.05% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Valneva-43.08% -43.05% -16.23% Rapt Therapeutics N/A -81.47%-70.24% SummaryValneva beats Rapt Therapeutics on 9 of the 17 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$121.21M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.4221.3126.1719.90Price / Sales86.59278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book0.707.518.025.38Net Income-$129.87M-$55.05M$3.15B$248.50M7 Day Performance-17.68%2.07%1.48%2.06%1 Month Performance1.34%4.84%3.66%4.86%1 Year Performance-63.19%5.37%34.68%20.24% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics4.1833 of 5 stars$8.01+9.3%$24.00+199.6%-64.1%$121.21M$1.53M-0.4280VALNValneva1.9963 of 5 stars$5.56-1.1%$15.50+178.8%-20.3%$473.10M$183.52M-4.67700Positive NewsMAZEMaze TherapeuticsN/A$10.73-4.0%$25.67+139.2%N/A$469.97M$167.50M0.00121Positive NewsSEPNSepterna1.7138 of 5 stars$10.53+0.6%$26.75+154.0%N/A$469.22M$1.08M0.00N/APositive NewsAMLXAmylyx Pharmaceuticals3.5275 of 5 stars$5.02-0.6%$10.14+102.0%+277.6%$447.48M$87.37M-1.61200CGEMCullinan Therapeutics2.2404 of 5 stars$7.58-1.2%$30.00+295.8%-52.4%$447.30MN/A-2.6030Positive NewsGap UpATYRaTyr Pharma2.7582 of 5 stars$4.98-4.6%$20.20+305.6%N/A$443.22M$230K-6.1553High Trading VolumeSIGASiga Technologies1.3897 of 5 stars$6.19+1.1%N/A-14.4%$442.21M$138.72M9.2440TRMLTourmaline Bio2.5316 of 5 stars$17.02+2.3%$49.33+189.9%+29.0%$437.07MN/A-5.3044PGENPrecigen4.1912 of 5 stars$1.48+2.1%$6.00+305.4%+8.1%$436.87M$3.92M-2.64190News CoveragePositive NewsMREOMereo BioPharma Group2.3991 of 5 stars$2.74-3.9%$7.60+177.4%-16.8%$435.66M$10M-39.1440 Related Companies and Tools Related Companies Valneva Competitors Maze Therapeutics Competitors Septerna Competitors Amylyx Pharmaceuticals Competitors Cullinan Therapeutics Competitors aTyr Pharma Competitors Siga Technologies Competitors Tourmaline Bio Competitors Precigen Competitors Mereo BioPharma Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPT Stock Alerts